TELMISIGN TRIO Tablet is a fixed-dose combination of three proven antihypertensive agents: Telmisartan (an angiotensin II receptor blocker), Amlodipine (a calcium channel blocker), and Hydrochlorothiazide (a thiazide diuretic). This triple-action formulation is crafted for patients who do not achieve adequate blood pressure control with dual therapy alone, and who require a more intensive and consolidated approach to managing hypertension.
Telmisartan works by inhibiting the angiotensin II receptor, leading to vasodilation and a reduction in systemic vascular resistance. Amlodipine, by blocking calcium channels in the vascular smooth muscle, complements Telmisartan’s action by further relaxing the blood vessels and reducing the workload on the heart. Hydrochlorothiazide, meanwhile, increases the excretion of sodium and water from the kidneys, reducing blood volume and thereby further lowering blood pressure. Together, these agents work synergistically to deliver consistent, 24-hour blood pressure control.
TELMISIGN TRIO is particularly effective for hypertensive patients with coexisting cardiovascular risks such as left ventricular hypertrophy, renal impairment, diabetes, or obesity. The once-daily dosing simplifies treatment protocols, improves patient adherence, and minimizes pill burden.
Manufactured under the global pharmaceutical compliance framework of BluepillExpress, TELMISIGN TRIO is developed in GMP, WHO-GMP, and ISO-certified facilities. The product undergoes extensive analytical validation, including assays for individual active ingredients, blend uniformity, dissolution profiles, impurity profiling, and microbial testing. Each batch is rigorously checked for compliance with international pharmacopoeial standards before release.
Clinically, TELMISIGN TRIO helps reduce the risk of stroke, heart attack, and kidney complications related to uncontrolled hypertension. Patients report good tolerability, with adverse effects such as dizziness, fatigue, ankle swelling, or mild electrolyte imbalance occurring infrequently. Periodic monitoring of kidney function, electrolytes, and blood pressure is advised during chronic use, particularly in elderly or renal-compromised individuals.
The product is available in tamper-proof, moisture-resistant packaging, ensuring a long shelf life and product integrity even in high-humidity regions. TELMISIGN TRIO offers a comprehensive and clinically validated solution for high-risk hypertensive patients in need of robust, multi-faceted blood pressure management.
It is contraindicated in pregnancy, patients with severe renal or hepatic dysfunction, and in those with hypersensitivity to sulfonamide-derived drugs. Care should also be taken in patients with electrolyte imbalance, volume depletion, or severe cardiac failure.
With TELMISIGN TRIO, BluepillExpress delivers a globally competitive, high-efficacy solution for physicians aiming to optimize hypertension outcomes in complex cases.
Description provided by Bluepill Express.
Telmisartan, Amlodipine, Hydrochlorothiazide
Triple-combination antihypertensive for multi-drug therapy in hypertension management
Telmisartan inhibits angiotensin II receptors; Amlodipine blocks calcium channels; Hydrochlorothiazide acts as diuretic
For patients inadequately controlled on dual therapy with coexisting cardiovascular risks
Produced in GMP, WHO-GMP, and ISO-certified facilities
Involves assays for active ingredients, blend uniformity, dissolution, impurities, and microbial testing
Tamper-proof, moisture-resistant packaging for extended shelf life
Pregnancy, severe renal/hepatic dysfunction, sulfonamide hypersensitivity
Reduces risk of stroke, heart attack, kidney complications with sustained 24-hour blood pressure control
Specifications
Formulation Type
Fixed-dose combination tablet
Dosage Strength
Variable strengths combining Telmisartan, Amlodipine, and Hydrochlorothiazide
Pharmacological Class
Angiotensin II receptor blocker, Calcium channel blocker, Thiazide diuretic
Shelf Life
Typically 24 months in recommended storage conditions
Storage Conditions
Store in a cool, dry place away from direct sunlight and moisture
Packaging Type
Blister packs in tamper-evident, moisture-resistant material
Safety Monitoring
Requires periodic kidney function, electrolyte levels, and blood pressure checks during therapy
Regulatory Compliance
Complies with international pharmacopoeial and pharmaceutical manufacturing standards
Manufacturer
Dr Precision under BluepillExpress global pharmaceutical compliance framework
Common Side Effects
Dizziness, fatigue, ankle swelling, mild electrolyte imbalance (infrequent)